Business Context and Reporting Period
Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2005
Business Overview: The Company operates as a physician management organization, providing neonatal, maternal-fetal, and pediatric services through affiliated professional contractors. During the nine months ended September 30, 2005, the Company acquired 12 physician group practices.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2005 |
Nine Months Ended Sep 30, 2005 |
Nine Months Ended Sep 30, 2004 |
|---|---|---|---|
| Net Patient Service Revenue | $178,099 | $516,005 | $458,636 |
| Income from Operations | $44,813 | $118,011 | $116,029 |
| Net Income | $28,057 | $73,167 | $72,494 |
| Diluted EPS | $1.16 | $3.07 | $2.88 |
| Operating Margin | 25.2% | 22.9% | 25.3% |
| Cash and Cash Equivalents | $4,778 | $4,778 | $30,907 (End of Period 2004) |
| Working Capital | $9,083 | $9,083 | $21,180 (Dec 31, 2004) |
| Net Cash from Operating Activities | N/A | $114,593 | $80,336 |
| Net Cash Used in Investing Activities | N/A | $(96,257) | $(45,814) |
| Long-Term Debt & Capital Leases | $666 | $666 | $693 |
Note: Working capital calculated as Total Current Assets ($156,337) minus Total Current Liabilities ($147,254).
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 12.5% year-over-year for both the three and nine-month periods. Approximately 52.6% to 61.6% of this growth was attributable to acquisitions completed after June 30, 2004. Same-unit revenue increased 4.9% (Q3) and 6.2% (YTD), driven by increased neonatal intensive care unit patient days and volume growth in maternal-fetal services.
- Expense Increases: Operating expenses rose significantly due to acquisition-related costs and new compensation structures. General and administrative expenses increased 24.3% (Q3) and 26.7% (YTD), largely driven by $3.7 million in equity-based compensation from restricted stock awards and a $6.0 million increase in liability reserves for legal settlements.
- Margin Compression: Operating margins decreased from 26.2% to 25.2% in Q3 and from 25.3% to 22.9% YTD. This decline is primarily attributed to the $4.7 million equity-based compensation expense and the $6.0 million legal reserve adjustment, which offset operational efficiencies.
- Liquidity Shift: Cash and cash equivalents decreased from $7.0 million at year-end 2004 to $4.8 million at September 30, 2005. Working capital declined by $12.1 million due to funds used for acquisitions ($85.7 million) and repayment of the $54.0 million line of credit.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions: The Company spent approximately $85.7 million in cash to acquire 12 physician practices in the first nine months of 2005. Contingent consideration of up to $10.0 million may be required. A subsequent acquisition of $6.0 million was completed after the period end.
- Share Repurchase Program: On November 2, 2005, the Board authorized a program to repurchase up to $50.0 million of common stock.
- Legal Contingencies: The Company is subject to ongoing investigations by the FTC regarding competition issues and federal/state authorities regarding Medicaid and TRICARE billing practices (including a "qui tam" whistleblower complaint). In Q1 2005, reserves were increased by $6.0 million related to a settlement offer. Management cannot predict the outcome or potential material adverse effects.
- Accounting Changes: The Company currently uses the intrinsic value method for stock-based compensation but will adopt FAS 123R (fair value method) effective January 1, 2006, which is expected to significantly impact future results of operations.
- Debt Status: The Company has a $225 million revolving line of credit. As of September 30, 2005, there was no outstanding principal balance, though $16.0 million in letters of credit were outstanding.
Investor Verification Checklist
- Legal Reserve Adequacy: Verify if the $6.0 million reserve for Medicaid/TRICARE investigations is sufficient given the ongoing "qui tam" complaint and potential for additional state inquiries.
- Acquisition Integration: Assess the performance of the 12 practices acquired in 2005 to ensure they meet revenue and margin projections.
- Impact of FAS 123R: Review the pro forma net income figures provided in the filing to understand the potential reduction in earnings once fair value accounting for stock options is adopted in 2006.
- Payor Mix Trends: Monitor the shift toward government-sponsored programs, which pay less than commercial insurers, and its impact on future contractual adjustments and uncollectibles.
- Share Repurchase Execution: Track the execution of the new $50 million share repurchase program and its impact on cash reserves and leverage ratios.